Financials

  • Market Capitalization 8.06 B
  • Employee 691
  • Founded 2014
  • CEO Rich Adcock
  • Website www.immunitybio.com
  • Headquarter Delaware, United States
  • FIGI BBG007T9DYW9
  • Industry Biotecnologia
Ricavi totali
Utile netto
Utile base per azione (EPS base)
Debito totale
Liquidità libera
Disponibilità liquide e mezzi equivalenti
Rapporto prezzo/utili
-9.02
Rapporto prezzo/fatturato
51.72

Related tickers

#NomePrezzo24h %7d %1M %1Y %Valore di MercatoUltimi 7 Giorni
1023
TGTX
TG Therapeutics, Inc. - Common Stock
55.37 USD+0.87%-2.19%+10.43%+44.61%8.48 B USD
1033
PCVX
Vaxcyte, Inc. - Common Stock
56.45 USD+0.43%-1.31%+13.88%+33.45%8.15 B USD
1042
IMVT
Immunovant, Inc. - Common Stock
39.23 USD+1.19%+0.72%+18.13%+104.22%8.05 B USD
1061
KNSA
Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares
61.50 USD-0.77%-7.50%+17.82%+55.13%7.69 B USD

Notizie